tiprankstipranks
Trending News
More News >
Canopy Growth (TSE:WEED)
:WEED
Advertisement

Canopy Growth (WEED) AI Stock Analysis

Compare
2,215 Followers

Top Page

TSE:WEED

Canopy Growth

(NASDAQ:WEED)

Select Model
Select Model
Select Model
Underperform 40 (OpenAI - 4o)
Rating:40Underperform
Price Target:
C$1.50
▼(-23.08% Downside)
Canopy Growth's overall stock score is primarily impacted by its poor financial performance, characterized by significant losses and negative cash flows. Technical analysis indicates bearish momentum, and the valuation is unattractive due to a negative P/E ratio and lack of dividend yield. Despite some positive developments in the Canadian market, the company's financial challenges and market conditions weigh heavily on its stock score.
Positive Factors
Canadian Market Growth
Significant growth in the Canadian market indicates strong demand and effective market positioning, which could drive sustained revenue increases.
Cost Savings Initiatives
Effective cost management enhances profitability and operational efficiency, contributing to long-term financial health and competitive advantage.
Positive Cash Position
A strong cash position relative to debt improves financial flexibility, enabling strategic investments and resilience against market fluctuations.
Negative Factors
International Market Challenges
Challenges in international markets, particularly in Europe, could hinder global expansion efforts and limit revenue diversification.
Negative Profit Margins
Persistent negative profit margins indicate ongoing operational inefficiencies, which could impact long-term sustainability and investor confidence.
Regulatory Risks
Potential regulatory changes in Canada could affect market access and demand, posing risks to revenue from the medical cannabis segment.

Canopy Growth (WEED) vs. iShares MSCI Canada ETF (EWC)

Canopy Growth Business Overview & Revenue Model

Company DescriptionCanopy Growth Corporation is a leading Canadian cannabis company that operates in the production and distribution of cannabis and hemp-based products. Founded in 2013, the company operates across various sectors, including recreational and medical cannabis products, as well as CBD-infused beverages and edibles. Canopy Growth is known for its diverse portfolio of brands such as Tweed, Spectrum Therapeutics, and Houseplant, catering to a wide range of consumer preferences in both the domestic and international markets.
How the Company Makes MoneyCanopy Growth generates revenue primarily through the sale of cannabis products, which includes both dried flower and oils for recreational and medical use. The company's revenue model is largely driven by its ability to scale production and leverage its extensive distribution networks. Key revenue streams include direct sales to consumers through retail outlets, wholesale distribution to other retailers, and export sales to international markets where cannabis is legal. Additionally, Canopy Growth has formed significant partnerships, including collaborations with beverage companies to develop cannabis-infused drinks, which further enhance its product offerings and market reach. The company also invests in research and development to innovate within the cannabis space, creating new products that tap into emerging consumer trends.

Canopy Growth Earnings Call Summary

Earnings Call Date:Nov 07, 2025
(Q2-2026)
|
% Change Since: |
Next Earnings Date:Feb 06, 2026
Earnings Call Sentiment Neutral
The call presented a mixed view: strong growth in Canadian markets and effective cost savings were offset by significant challenges in international markets and potential regulatory risks in Canada.
Q2-2026 Updates
Positive Updates
Strong Canadian Adult-Use Cannabis Growth
Net revenue in the Canadian adult-use cannabis business increased by 30% year-over-year in Q2, driven by demand for Claybourne infused pre-rolls and Tweed and 7ACRES All-In-One vapes.
Canadian Medical Cannabis Revenue Increase
Net revenue in the Canadian medical cannabis business grew by 17% year-over-year, marking another consecutive quarter of growth and supported by a 20% increase in patient registrations.
SG&A Savings Surpass Target
The SG&A savings program delivered over $21 million in annualized savings, surpassing the original $20 million target ahead of schedule.
Positive Cash Position and Reduced Debt
Canopy Growth reported $298 million in cash and cash equivalents, exceeding debt balances by $70 million, and prepaid USD 50 million on its senior secured term loan, capturing USD 6.5 million in annualized interest savings.
Negative Updates
International Market Challenges
Net revenues in international markets declined by $3 million, with a 39% year-over-year decrease due to supply chain issues and internal process challenges, particularly affecting Europe.
Canadian Medical Cannabis Reimbursement Proposal
The Canadian federal government's proposal to reduce reimbursement for veterans using prescribed medical cannabis could impact access and quality of care, posing a potential risk to the business.
Company Guidance
During Canopy Growth's Second Quarter Fiscal 2026 Financial Results Conference Call, the company reported a robust performance in its Canadian cannabis business, with net revenue in the adult-use segment increasing by 30% year-over-year, and the medical cannabis segment growing by 17%. The company achieved a significant milestone by narrowing its adjusted EBITDA loss to $3 million, compared to a $6 million loss the previous year. This improvement was driven by rigorous cost-saving initiatives, surpassing a $20 million target with $21 million in annualized savings, and a stronger financial position with $298 million in cash and cash equivalents, exceeding debt balances by $70 million. Canopy Growth also highlighted its plans to enhance its cultivation standards and expand its product lineup, including the launch of the new VEAZY Vaporizer by Storz & Bickel, which contributed to sequential revenue growth. However, the company acknowledged challenges in international markets, specifically in Europe, where net revenues declined by $3 million due to supply constraints, but expressed commitment to improving supply chain execution to stabilize operations by fiscal year's end.

Canopy Growth Financial Statement Overview

Summary
Canopy Growth faces significant financial challenges with substantial net losses and negative cash flows. Despite a slight revenue increase, the company struggles with profitability, as indicated by a negative net profit margin and return on equity. The balance sheet shows moderate leverage, but the negative cash flow health is concerning.
Income Statement
30
Negative
Canopy Growth's income statement shows significant challenges with profitability. The company has a negative net profit margin of -222.35% in the TTM, indicating substantial losses relative to revenue. Although there is a slight revenue growth of 2.20% in the TTM, the EBIT and EBITDA margins remain deeply negative, reflecting ongoing operational inefficiencies. The gross profit margin is positive at 29.56%, but the overall financial health is concerning due to persistent net losses.
Balance Sheet
40
Negative
The balance sheet reveals a moderate debt-to-equity ratio of 0.72 in the TTM, suggesting manageable leverage compared to equity. However, the return on equity is significantly negative at -112.78%, highlighting the company's inability to generate profit from shareholders' equity. The equity ratio stands at 54.05%, indicating a reasonable proportion of equity financing, but the negative ROE is a major concern.
Cash Flow
35
Negative
Cash flow analysis indicates negative operating cash flow and free cash flow in the TTM, with a free cash flow growth rate of -24.79%. The operating cash flow to net income ratio is negative, suggesting cash outflows exceed net losses. The free cash flow to net income ratio is slightly positive at 1.07, indicating some alignment between cash flow and accounting losses, but overall cash flow health is weak.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue274.92M269.00M297.15M333.25M510.32M546.65M
Gross Profit74.52M79.51M80.88M-98.38M-143.60M66.96M
EBITDA-410.31M-479.31M-312.83M-2.88B-52.98M-1.55B
Net Income-512.50M-598.12M-657.27M-3.28B-310.04M-1.74B
Balance Sheet
Total Assets904.67M917.70M1.30B2.44B5.62B6.82B
Cash, Cash Equivalents and Short-Term Investments143.63M131.47M203.46M782.60M1.37B2.30B
Total Debt327.80M348.40M668.00M1.31B1.50B1.58B
Total Liabilities415.69M430.49M799.82M1.68B1.98B3.20B
Stockholders Equity488.98M487.21M500.37M758.43M3.59B3.48B
Cash Flow
Free Cash Flow-133.14M-177.03M-285.95M-568.10M-593.92M-639.87M
Operating Cash Flow-124.31M-165.75M-281.95M-557.55M-545.81M-465.73M
Investing Cash Flow-15.46M-47.79M241.59M433.38M230.82M-884.11M
Financing Cash Flow68.34M148.66M-465.06M-19.69M-45.53M1.26B

Canopy Growth Technical Analysis

Technical Analysis Sentiment
Negative
Last Price1.95
Price Trends
50DMA
1.92
Negative
100DMA
1.81
Negative
200DMA
1.92
Negative
Market Momentum
MACD
-0.09
Positive
RSI
41.78
Neutral
STOCH
18.16
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:WEED, the sentiment is Negative. The current price of 1.95 is above the 20-day moving average (MA) of 1.80, above the 50-day MA of 1.92, and above the 200-day MA of 1.92, indicating a bearish trend. The MACD of -0.09 indicates Positive momentum. The RSI at 41.78 is Neutral, neither overbought nor oversold. The STOCH value of 18.16 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:WEED.

Canopy Growth Risk Analysis

Canopy Growth disclosed 87 risk factors in its most recent earnings report. Canopy Growth reported the most risks in the "Legal & Regulatory" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Canopy Growth Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
65
Neutral
C$1.33B51.183.34%22.20%
64
Neutral
C$2.22B54.062.42%6.18%-28.69%
51
Neutral
$7.86B-0.30-43.30%2.27%22.53%-2.21%
49
Neutral
C$3.07B-27.61%-3.38%-31.35%
48
Neutral
C$1.78B-9.95%4.27%3.41%
47
Neutral
C$362.43M-10.76%23.87%-19.57%
40
Underperform
C$555.90M-0.39-98.42%-4.24%55.82%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
TSE:WEED
Canopy Growth
1.65
-4.25
-72.03%
TSE:ACB
Aurora Cannabis
6.38
-0.30
-4.49%
TSE:CRON
Cronos Group
3.47
0.67
23.93%
TSE:CURA
Curaleaf Holdings
3.72
0.78
26.53%
TSE:GTII
Green Thumb Industries
9.82
-2.59
-20.87%
TSE:TRUL
Trulieve Cannabis
9.25
-0.47
-4.84%

Canopy Growth Corporate Events

Canopy Growth Shows Financial Improvement in Q2 FY2026
Nov 8, 2025

Canopy Growth Corporation is a leading cannabis company operating in the medical and adult-use cannabis markets, with a focus on innovation and quality products across Canada, Europe, and Australia.

Business Operations and StrategyFinancial Disclosures
Canopy Growth Strengthens Financial Performance in Q2 FY2026
Positive
Nov 7, 2025

Canopy Growth reported a significant improvement in its financial performance for the second quarter of fiscal 2026, with a notable increase in Canada adult-use and medical cannabis revenues. The company’s disciplined cost management and strategic focus have resulted in a stronger balance sheet, resolving previous concerns about its ability to continue as a going concern. Despite challenges in international markets and a decrease in revenue from its Storz & Bickel segment, the company has managed to reduce its operating loss and improve its adjusted EBITDA. This financial progress positions Canopy Growth for sustained growth and resilience in the competitive cannabis industry.

The most recent analyst rating on (TSE:WEED) stock is a Sell with a C$1.50 price target. To see the full list of analyst forecasts on Canopy Growth stock, see the TSE:WEED Stock Forecast page.

Financial Disclosures
Canopy Growth to Announce Q2 Fiscal 2026 Financial Results
Neutral
Oct 24, 2025

Canopy Growth Corporation will announce its second quarter fiscal year 2026 financial results on November 7, 2025. The announcement will be followed by an audio webcast featuring CEO Luc Mongeau and CFO Tom Stewart. This release is significant as it provides insights into the company’s financial health and strategic positioning in the cannabis industry, potentially impacting stakeholders and market perceptions.

The most recent analyst rating on (TSE:WEED) stock is a Hold with a C$2.00 price target. To see the full list of analyst forecasts on Canopy Growth stock, see the TSE:WEED Stock Forecast page.

Business Operations and StrategyShareholder Meetings
Canopy Growth Shareholders Approve Key Proposals
Positive
Oct 14, 2025

On October 10, 2025, Canopy Growth Corporation reconvened its 2025 Annual General and Special Meeting of Shareholders, where shareholders voted on several key proposals. These included the election of directors, the appointment of PKF O’Connor Davies as auditors, a share consolidation proposal, and an advisory vote on executive compensation. All proposals were approved, indicating shareholder support for the company’s strategic decisions and governance structure.

The most recent analyst rating on (TSE:WEED) stock is a Hold with a C$2.00 price target. To see the full list of analyst forecasts on Canopy Growth stock, see the TSE:WEED Stock Forecast page.

Business Operations and StrategyProduct-Related Announcements
Canopy Growth Dedicates DOJA Facility to Canadian Medical Cannabis
Positive
Oct 8, 2025

Canopy Growth has announced that its DOJA facility in Kelowna, British Columbia, will now exclusively produce craft cannabis for the Spectrum Therapeutics medical portfolio in Canada. This move underscores Canopy Growth’s commitment to the medical cannabis market and aims to strengthen its position by focusing on high-quality, small-batch production for registered medical patients, including veterans.

The most recent analyst rating on (TSE:WEED) stock is a Hold with a C$2.00 price target. To see the full list of analyst forecasts on Canopy Growth stock, see the TSE:WEED Stock Forecast page.

Delistings and Listing ChangesShareholder Meetings
Canopy Growth Adjourns Shareholder Meeting Due to Lack of Quorum
Neutral
Sep 26, 2025

Canopy Growth Corporation has adjourned its Annual General and Special Meeting of Shareholders due to a lack of quorum and will reconvene on October 10. The company is actively encouraging shareholders to vote before the new meeting date to ensure quorum is met, which is a requirement for its NASDAQ listing. This adjournment allows shareholders additional time to participate in the decision-making process, potentially impacting the company’s governance and future strategies.

The most recent analyst rating on (TSE:WEED) stock is a Hold with a C$2.00 price target. To see the full list of analyst forecasts on Canopy Growth stock, see the TSE:WEED Stock Forecast page.

Shareholder Meetings
Canopy Growth Extends Proxy Voting Deadline to Ensure Quorum
Neutral
Sep 24, 2025

Canopy Growth has extended the proxy voting deadline for its upcoming annual general and special meeting to ensure a quorum is achieved. The extension aims to give shareholders more time to vote, as the company is close to reaching the required quorum for the meeting, which is crucial for transacting business.

The most recent analyst rating on (TSE:WEED) stock is a Hold with a C$2.00 price target. To see the full list of analyst forecasts on Canopy Growth stock, see the TSE:WEED Stock Forecast page.

Delistings and Listing ChangesShareholder Meetings
Canopy Growth Urges Shareholder Participation Ahead of Key Meeting
Neutral
Sep 19, 2025

Canopy Growth is urging its shareholders to vote in the upcoming annual general and special meeting to help reach the quorum needed to avoid delays and additional costs. The company emphasizes the importance of shareholder participation, regardless of the number of shares owned, to meet the NASDAQ listing requirements and ensure the meeting proceeds as planned.

The most recent analyst rating on (TSE:WEED) stock is a Hold with a C$2.00 price target. To see the full list of analyst forecasts on Canopy Growth stock, see the TSE:WEED Stock Forecast page.

Business Operations and StrategyExecutive/Board Changes
Canopy Growth Appoints Tom Stewart as CFO to Enhance Financial Strategy
Positive
Sep 17, 2025

Canopy Growth has appointed Tom Stewart as Chief Financial Officer to strengthen its operational discipline and financial stability. His leadership is expected to drive performance improvements and support the company’s fiscal year 2026 strategy, focusing on structural efficiency and disciplined capital management.

The most recent analyst rating on (TSE:WEED) stock is a Hold with a C$2.00 price target. To see the full list of analyst forecasts on Canopy Growth stock, see the TSE:WEED Stock Forecast page.

Business Operations and StrategyPrivate Placements and Financing
Canopy Growth Enhances Financial Position with Early Loan Prepayment
Positive
Sep 15, 2025

Canopy Growth has made an early prepayment of US$25 million on its senior secured term loan, completing its obligation under an agreement with lenders. This move is expected to reduce the company’s annual cash interest expense by US$6.5 million, strengthening its financial position and reflecting its strategic focus on debt reduction.

The most recent analyst rating on (TSE:WEED) stock is a Hold with a C$2.00 price target. To see the full list of analyst forecasts on Canopy Growth stock, see the TSE:WEED Stock Forecast page.

Business Operations and StrategyPrivate Placements and Financing
Canopy Growth Strengthens Financial Position with Early Loan Prepayment
Positive
Sep 15, 2025

Canopy Growth Corporation announced the early prepayment of a US$25 million term loan, completing an aggregate of US$50 million in prepayments under an agreement with its lenders. This financial move is expected to reduce the company’s annual cash interest expense by US$6.5 million, thereby strengthening its financial position and demonstrating prudent fiscal management. The accelerated debt reduction is part of Canopy Growth’s strategy to enhance its financial stability and operational efficiency, potentially benefiting stakeholders by improving the company’s market positioning.

The most recent analyst rating on (TSE:WEED) stock is a Hold with a C$2.00 price target. To see the full list of analyst forecasts on Canopy Growth stock, see the TSE:WEED Stock Forecast page.

Product-Related Announcements
STORZ & BICKEL Unveils VEAZY: A New Compact Vaporizer
Positive
Sep 9, 2025

STORZ & BICKEL, a subsidiary of Canopy Growth Corporation, has launched the VEAZY, a compact and accessible vaporizer, expanding its premium product portfolio. The VEAZY, available in four colors, offers portability, style, and high performance at a competitive price, aiming to reach a broader audience and enhance the company’s market presence in over 100 countries.

The most recent analyst rating on (TSE:WEED) stock is a Hold with a C$2.00 price target. To see the full list of analyst forecasts on Canopy Growth stock, see the TSE:WEED Stock Forecast page.

Shareholder Meetings
ISS Endorses Canopy Growth’s Resolutions Ahead of Shareholder Meeting
Neutral
Sep 3, 2025

Canopy Growth Corporation has received a recommendation from Institutional Shareholder Services Inc. (ISS) for shareholders to vote in favor of all resolutions at the upcoming Annual General and Special Meeting. This endorsement by ISS, a respected proxy advisory firm, is significant as it influences many institutional investors. Achieving a quorum at the meeting is crucial for Canopy Growth to avoid additional costs, and shareholders are urged to vote promptly.

The most recent analyst rating on (TSE:WEED) stock is a Hold with a C$2.00 price target. To see the full list of analyst forecasts on Canopy Growth stock, see the TSE:WEED Stock Forecast page.

Business Operations and StrategyPrivate Placements and Financing
Canopy Growth Launches New Equity Program
Positive
Aug 29, 2025

On August 29, 2025, Canopy Growth Corporation announced the establishment of a new at-the-market equity program allowing the company to issue and sell up to $200 million of common shares in the U.S. and Canada. This program aims to strengthen Canopy Growth’s financial position by potentially funding future acquisitions, investments, and general corporate purposes. The equity distribution agreement with BMO Capital Markets Corp. and BMO Nesbitt Burns Inc. replaces a previous agreement and provides flexibility in sales methods, subject to market conditions and other factors. The program’s impact could enhance Canopy Growth’s market positioning and provide necessary capital for strategic initiatives.

The most recent analyst rating on (TSE:WEED) stock is a Hold with a C$2.00 price target. To see the full list of analyst forecasts on Canopy Growth stock, see the TSE:WEED Stock Forecast page.

Executive/Board ChangesShareholder Meetings
Canopy Growth Urges Shareholders to Vote in Upcoming Meeting
Neutral
Aug 15, 2025

Canopy Growth Corporation has announced the mailing and filing of proxy materials for its 2025 annual general and special meeting of shareholders. The company emphasizes the importance of shareholder voting to avoid additional costs and achieve a quorum, which is essential for the meeting to proceed. Shareholders will vote on several key issues, including the election of directors, auditor re-appointment, a share consolidation proposal, and an advisory vote on executive compensation. The board recommends voting in favor of all resolutions.

The most recent analyst rating on (TSE:WEED) stock is a Sell with a C$1.50 price target. To see the full list of analyst forecasts on Canopy Growth stock, see the TSE:WEED Stock Forecast page.

Canopy Growth’s Earnings Call: Mixed Sentiments and Strategic Moves
Aug 13, 2025

The recent earnings call of Canopy Growth painted a picture of significant top-line growth in cannabis revenue, alongside successful cost reduction initiatives and improved cash flow. While these positive outcomes were evident, the call also highlighted challenges in certain segments like Storz & Bickel, compressed margins, and specific international market difficulties, resulting in a slightly mixed sentiment overall.

Canopy Growth Reports Strong Cannabis Revenue Growth
Aug 9, 2025

Canopy Growth Corporation is a leading cannabis company operating globally, known for its innovative products and commitment to enhancing lives through cannabis. The company, headquartered in Smiths Falls, Ontario, operates in the cannabis sector, providing both recreational and medical cannabis products, as well as vaporizers and accessories through its Storz & Bickel brand.

Business Operations and StrategyExecutive/Board ChangesFinancial Disclosures
Canopy Growth Appoints Margaret Shan Atkins to Board
Positive
Aug 8, 2025

On August 6, 2025, Canopy Growth appointed Margaret Shan Atkins to its Board of Directors, enhancing the board with her extensive experience in retail strategy, consumer goods, and finance. The company reported a 9% increase in net revenue for Q1 FY2026, driven by strong performance in the Canadian adult-use cannabis market, despite a decrease in gross margin due to product mix changes and lower sales in high-margin markets. The company is focused on improving margins and maintaining growth momentum in the cannabis sector, while Storz & Bickel prepares to launch a new vaporizer to boost consumer interest.

The most recent analyst rating on (TSE:WEED) stock is a Sell with a C$2.00 price target. To see the full list of analyst forecasts on Canopy Growth stock, see the TSE:WEED Stock Forecast page.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Nov 08, 2025